MedTrace Logo

Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

NCT07671755 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-06-26

No results posted yet for this study

Summary

This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.

Conditions

  • Clinical Response
  • Radiological Response

Interventions

DRUG

colistin plus cefoperazone-sulbactam combination group

Combination therapy

DRUG

Colistin

Monotherapy

Sponsors & Collaborators

  • Shaheed Mohtarma Benazir Bhutto Institue of Trauma

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-12-30
Completion
2026-04-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671755 on ClinicalTrials.gov